



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



Publication number: **0 515 681 A1**

**EUROPEAN PATENT APPLICATION**  
published in accordance with Art.  
158(3) EPC

Application number: **91903606.1**

Int. Cl.<sup>5</sup>: **C07K 5/06, C07K 5/08,  
A61K 37/02**

Date of filing: **12.02.91**

International application number:  
**PCT/JP91/00167**

International publication number:  
**WO 91/12266 (22.08.91 91/19)**

Priority: **15.02.90 JP 34568/90**

Date of publication of application:  
**02.12.92 Bulletin 92/49**

Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IT LI LU NL SE**

Applicant: **FUJISAWA PHARMACEUTICAL CO.,  
LTD.**  
**4-7, Doshomachi 3-chome Chuo-ku  
Osaka-shi Osaka 541(JP)**

Inventor: **MATSUO, Masaaki**  
**4-12, Nakasakurazuka 5-chome**  
**Toyonaka-shi, Osaka 560(JP)**  
Inventor: **HAGIWARA, Daijiro**  
**20-11, Kindacho 2-chome**  
**Moriguchi-shi, Osaka 570(JP)**  
Inventor: **MIYAKE, Hiroshi**  
**86, Jodojinishida-cho, Sakyo-ku**  
**Kyoto-shi, Kyoto 606(JP)**

Representative: **Türk, Gille, Hrabal, Leifert**  
**Brucknerstrasse 20**  
**W-4000 Düsseldorf 13(DE)**

**PEPTIDE COMPOUND.**

A tachykinin-antagonistic compound of the following general formula and its salt:  $R^1-A^1-D-Trp(R^2)-A^2-R^3$ , wherein  $R^1$  represents hydrogen or an amino protective group,  $R^2$  represents an amino protective group,  $R^3$  represents an aryl-lower alkoxy, N-(lower) alkyl, or N-(lower) alkyl amino group,  $A^1$  represents a single bond or a single amino acid residue, and  $A^2$  represents a single amino acid residue other than Phe.

EP 0 515 681 A1

Field of Art

The present invention relates to a new peptide compound and the salt thereof, and more precisely, to a new peptide compound and the salt thereof which has a pharmaceutical activity such as tachykinin antagonism, especially substance P compound antagonism, neurokinin A antagonism, neurokinin B antagonism, and the like, and the process for the preparation of the above compound and tachykinin antagonism agent which contain the above compound as an active ingredient.

Background of Art

The object of the present invention is to provide a new and useful peptide compound and the salt thereof which has a pharmaceutical activity such as tachykinin antagonism, especially substance P compound antagonism, neurokinin A antagonism, neurokinin B antagonism, and the like.


The another object of the present invention is to provide a process for the preparation of the above peptide compound and the salt thereof.

The further object of the present invention is to provide a tachykinin antagonism agent which contains the above peptide compound or the salt thereof as an active ingredient.

The still further object of the present invention is to provide a use of the above peptide compound or the salt thereof as a tachykinin antagonism agent, especially substance P antagonism agent, neurokinin A antagonism agent, neurokinin B antagonism agent, and the like which is useful for therapeutics or prevention of tachykinin interstitial diseases of human or animals such as respiratory diseases (e.g., asthma, bronchitis, rhinitis, cough, expectoration, etc.), ophthalmic diseases (e.g., conjunctivitis, vernal conjunctivitis, etc.), cutaneous diseases (e.g., contact dermatitis, atopic dermatitis, urticaria, other kind of eczematoid dermatitis, etc.), inflammatory diseases (e.g., rheumatoid arthritis, osteoarthritis, etc.), pain or aches (e.g., migraine, headache, toothache, cancerous pain, backpain, etc.), and the like.

Disclosure of the Invention

The object compound of the present invention may be illustrated as the following general formula (I).




[wherein

- R<sup>1</sup> is hydrogen or amino-protective group
- R<sup>2</sup> is amino-protective group
- R<sup>3</sup> is ar(lower)alkoxy or N-(lower)alkyl-N-ar(lower)alkylamino
- A<sup>1</sup> is single bond or one amino acid residue
- A<sup>2</sup> is one amino acid residue excepting Phe.]


Best mode of the Invention

The object compound (I) of the present invention may be prepared by the method as illustrated as the following reaction scheme.

Preparation Process 1

( II a )


or its reactive  
derivative at the  
amino group, or the  
salt thereof



( II b )

or its reactive derivative  
at the carboxy group, or the  
salt thereof






( I a )

or the salt thereof


Preparation Process 2



( I a )

or the salt thereof

elimination reaction of  
amino-protective group



( I b )


or the salt thereof

Preparation Process 3




( I b )

or its reactive derivative at the  
amino group, or the salt thereof



( II c )


or its reactive derivative at the  
carboxy group, or the salt thereof



( I c )

or the salt thereof

#### Preparation Process 4



( I d )

or the salt thereof


elimination reaction of  
amino-protective group



( I e )

or the salt thereof


#### Preparation Process 5



( I e )

or its reactive derivative at the  
amino group, or the salt thereof

introduction reaction of  
amino-protective group



( I f )

or the salt thereof

[ In the above reaction scheme,  $R^{1a}$ ,  $R^{1b}$ ,  $R^{1c}$  are amino-protective group,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $A^1$ ,  $A^2$  are each as defined above ]

All the compounds (Ia), (Ib), (Ic), (Id), (Ie) and (If) illustrated on the above reaction scheme are included in the object compound (I) of the present invention. Accordingly, in the following explanation, these compounds (Ia) - (If) may be generally described as the object compound (I). All the compounds (IIa), (IIb) and (IIc) are used as the starting compound, and some of them are new and may be prepared according to the preparative examples described below or commonly used method.

In the present specification, amino acid, peptide, protective group, condensing agent may be illustrated by showing the abbreviation thereof that are defined at IUPAC-IUB.

In the case that amino acid or its residue is shown by using the above mentioned abbreviation without any specific instruction, it means compounds of L-form and D-form, compound and residue of D-form are shown with an indication of D-.

The suitable salt of the object compound (I) is a conventionally used non-toxic salt that include acid addition salt such as organic acid salt (e.g., acetic acid salt, trifluoroacetic acid salt, maleic acid salt, tartaric acid salt, methanesulfonic acid salt, benzenesulfonic acid salt, formic acid salt, toluenesulfonic acid salt, etc.), inorganic acid salt (e.g., hydrochloric acid salt, hydrobromic acid salt, hydriodic acid salt, sulfuric acid salt, nitric acid salt, phosphoric acid salt, etc.), salt with amino acid (e.g., arginine, aspartic acid, glutamic acid, etc.); metal salt such as alkali metal salt (e.g., sodium salt, potassium salt, etc.), alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.); ammonium salt; salt with organic base (e.g., trimethylamine, triethylamine, pyridine, picoline, dicyclohexylamine, N,N'-dibenzylethylenediamine, etc.); and the like.

Several definitions used in the afore or below description of the present specification, suitable example and explanation that is included in the scope of the present invention is described as follows.

"Lower" means  $C_1 - C_6$ , preferably  $C_1 - C_4$ .

"Amino acid" in "amino acid residue" which is used for  $A^1$  means aliphatic chain hydrocarbon compound, alicyclic hydrocarbon compound, aromatic hydrocarbon compound, heterocyclic compound, partially hydrogenated compound thereof or dehydrogenated compound thereof that is substituted with at least one amino group and at least one carboxy group, and these compounds may be further substituted with any other optical substituent(s).

Specifically suitable amino acid residue means bivalent residue of the above explained amino acid. The suitable example of thus explained amino acid include neutral amino acid such as glycine (gly), D-alanine or L-alanine (Ala),  $\beta$ -alanine ( $\beta$ -Ala), D- or L- valine (Val), D- or L- leucine (Leu), D- or L- isoleucine (Ile), D- or L- serine (Ser), D- or L- threonine (Thr), D- or L- cysteine (Cys), D- or L- methionine (Met), D- or L- phenylalanine (Phe), D- or L- tryptophan (Trp), D- or L- tyrosine (Tyr), D- or L- proline (Pro), D- or L- 4-hydroxyproline (Hyp), D- or L- pyroglutaminic acid (pGlu) or the like; acidic amino acid such as D- or L- glutamic acid (Glu), D- or L- aspartic acid (Asp), D- or L-  $\beta$ -aspartic acid ( $\beta$ -Asp), D- or L- glutamic acid (Gln), D- or L- asparagine (Asn) or the like; basic amino acid such as D- or L- lysine (Lys), D- or L- arginine (Arg), D- or L- histidine (His), D- or L- ornithine (Orn), D- or L- pyridylalanine (Pyr) or the like.

"Amino acid" in "amino acid residue" which is used for  $A^2$  means the same amino acid explained for  $A^1$  excepting L-Phe (L-phenylalanine). Accordingly,  $A^2$  includes D-phenylalanine and substituted L-phenylalanine. Suitable examples of amino acid for  $A^2$  include not only any exemplified amino acid for  $A^1$  but also N-methylphenylalanine, p-aminobenzoic acid, o-aminobenzoic acid, 1-aminonaphthalene-2-carboxylic acid, 2,3-dihydroindene-2-amino-2-carboxylic acid, pyrrole-2-carboxylic acid, 3-pyridylalanine, 3H-indole-

2-carboxylic acid, quinoline-2-carboxylic acid, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid or the like.

Suitable examples of the group which may be substituted for the above exemplified amino acid include lower alkyl, lower alkoxy, nitro, hydroxy, halogen, aryl, ar(lower)alkyl, heterocyclic group, heterocyclic(lower)-alkyl and the like. Any other groups such as the protective group conventionally used in the chemical field of amino acid and peptide may also be exemplified as substituent.

Suitable examples of lower alkyl include methyl, ethyl, propyl, butyl, tert-butyl, hexyl or the like. Suitable examples of lower alkoxy include methoxy, ethoxy, propoxy, butoxy or the like. Halogen includes fluorine, chlorine, bromine and iodine. Suitable examples of aryl include phenyl, naphthyl or the like. Suitable examples of ar(lower)alkyl include benzyl, phenethyl or the like. Suitable examples of heterocyclic group include furyl, oxazolyl, oxazolyl, oxazolidinyl, thienyl, thiazolyl, thiazolyl, pyrrolyl, pyrrolinyl, pyrrolidyl, pyridyl, pyranal, quinolyl, isoquinolyl or the like. Suitable examples of heterocyclic(lower)alkyl include 2-(furan-2-yl)ethyl, 2-(oxazoline-3-yl)ethyl, 2-(thiophene-2-yl)ethyl, 3-(thiazoline-3-yl)propyl, 3-(pyrrol-2-yl)propyl, 2-(imidazoline-2-yl)propyl or the like.

More suitable amino acid is  $\alpha$ -amino acid of which side chain is substituted with aromatic group residue or heterocyclic group residue, and most suitable examples of amino acid include alanine wherein carbon chain thereof is substituted with aromatic group residue or heterocyclic group residue at 3rd position (e.g., N-methylphenylalanine, D-phenylalanine, tyrosine, 3-thienylalanine, 3-pyridylalanine, tetrahydroisoquinoline-3-carboxylic acid, 2,3-dihydroindene-2-amino-2-carboxylic acid).

The group "-Trp(R<sup>2</sup>)-" means that R<sup>2</sup> is substituted at 1st position of indole ring of tryptophan residue.

Suitable examples of amino-protective group include the conventional protective one that is usually applied in the chemical field of amino acid or peptide, for example ar(lower)alkyl such as trityl, benzhydryl, benzyl, etc., dinitrophenyl, lower alkoxycarbonyl(lower)alkenyl such as 1-methoxycarbonyl-1-propene-1-yl, etc., aroyl(lower)alkenyl such as 1-benzoyl-1-propene-2-yl, hydroxyar(lower)alkylidene such as 2-hydroxybenzylidene, etc., silyl compound such as tri(lower)alkylsilyl (e.g., trimethylsilyl etc.), etc., and the acyl group as shown as follows.

Suitable acyl groups include aliphatic acyl, aromatic acyl, heterocyclic acyl, and aliphatic acyl that are substituted with aromatic residue or heterocyclic residue, and the like.

Suitable examples of aliphatic acyl include saturated or unsaturated, acyclic or cyclic acyl for example, cabamoyl, lower alkanoyl (e.g., formyl, acetyl, propionyl, butyryl, isobutyryl, varellyl, isovarellyl, pivaroyl, hexanoyl, etc.), lower alkane sulfonyl (e.g., mesyl, ethanesulfonyl, propanesulfonyl, etc.), lower alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, tert-butoxycarbonyl, etc.), lower alkenoyl (e.g., acryloyl, methacryloyl, crotonoyl, etc.), (C<sub>3</sub> - C<sub>7</sub>)cycloalkanecarbonyl (e.g., cyclohexanecarbonyl, etc.), amidino, protected carboxycarbonyl such as lower alkoxalyl (e.g., methoxalyl, ethoxalyl, tert-butoxalyl, etc.), and the like.

Suitable examples of aromatic acyl include aroyl (e.g., benzoyl, toluoyl, xuloyl, etc.), arenesulfonyl (e.g., benzenesulfonyl, tosyl, etc.), and the like.

Suitable examples of heterocyclic acyl include heterocyclic carbonyl (e.g., furoyl, thenoyl, nicotinoyl, isonicotinoyl, thiazolylcarbonyl, thiadiazolylcarbonyl, tetrazolylcarbonyl, morpholinocarbonyl, etc.) and the like.

Suitable examples of aliphatic acyl substituted with aromatic group include ar(lower)alkanoyl such as phenyl(lower)alkanoyl [e.g., phenylacetyl, phenylpropionyl, phenylhexanoyl, etc.], ar(lower)alkoxycarbonyl such as phenyl(lower)alkoxycarbonyl [e.g., benzyloxycarbonyl, phenetyloxycarbonyl, etc.] and the like.

Suitable examples of aliphatic acyl substituted with heterocyclic group include thienylacetyl, imidazolylacetyl, furylacetyl, terazolylacetyl, thiazolylacetyl, thiadiazolylacetyl, thienylpropyl, thiadiazolylpropionyl, and the like.

These acyl group may be further illustrated such as carboxy, lower alkyl [e.g., methyl ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl, etc.], halogen [i.e., chlorine, bromine, iodine, fluorine], carbamoyl, lower alkanoyl [e.g., formyl, acetyl, propionyl, etc.], ar(lower)alkanoyl [e.g., benzyl, etc.], lower alkyl [e.g., methyl ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl, etc.], lower alkoxycarbonyl [e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.], carboxy(lower)alkyl [e.g., carboxymethyl, carboxyethyl, etc.], protected carboxy(lower)alkyl [e.g., tert-butoxycarbonylmethyl, etc.] and the like.

Suitable examples of ar(lower)alkoxy of R<sup>3</sup> include benzyloxy, phenetyloxy, trityloxy, 3-phenyl-propoxy, 4-phenylbutoxy, benzhydryloxy and the like.

Suitable examples of N-(lower)alkyl-N-ar(lower)alkylamino of R<sup>3</sup> include N-methyl-N-benzylamino, N-methyl-N-phenethylamino, N-methyl-N-tritylamino, N-methyl-N-benzhydrylamino, N-ethyl-N-benzylamino, N-ethyl-N-phenethylamino and the like.

Suitable examples of each group of R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, A<sup>1</sup> and A<sup>2</sup> are explained as follows.

R<sup>1</sup> is hydrogen; acyl; carbamoyl; lower alkoxycarbonyl such as methoxycarbamoyl, ethoxycarbamoyl,

tert-butoxycarbamoyl, etc.; lower alkanoyl such as formyl, acetyl, propionyl, butyl, etc.; ar(lower)-alkoxycarbonyl such as mono- di- or tri-phenyl(lower)alkoxycarbonyl [e.g., benzyloxycarbonyl, etc.]; carbamoyl(lower)alkanoyl such as carbamoyl, succinamoyl, etc.; lower alkoxalyl such as methoxalyl, tert-butoxalyl, etc.;

- 5 di(lower)alkylamino(lower)alkanoyl such as dimethylaminoacetyl, diethylaminoacetyl, diethylaminopropionyl etc.; N-ar(lower)alkyl-N-lower-alkoxycarbonylamino(lower)alkanoyl such as N-mono-, di- or tri-phenyl(lower)-alkyl-N-lower-alkoxycarbonylamino(lower)alkanoyl e.g., N-benzyl-N-tert-butoxycarbonylaminoacetyl etc.]; heterocyclic(lower)alkanoyl optionally substituted with acylamino such as tetrazolyl(lower)alkanoyl [e.g., tetrazolylacetyl, etc.], acylaminothiazolyl(lower)alkanoyl which may have acylamino on alkanoyl such as  
 10 lower alkanoylaminothiazolyl(lower)alkanoyl [e.g., formamidothiazolylacetyl, etc.], thiazolyl(lower)alkanoyl having lower alkoxycarbonylamino or lower alkanoylamino on alkanoyl such as 2-formamidolacetyl, -2-tert-butoxycarbonylthiazolylacetyl, 2-formamidothiazolyl-2-acetoamidoacetyl, etc.;
- carboxy(lower)alkanoyl such as oxalo, carboxyacetyl, carboxypropionyl, carboxybutyl, carboxyvaleryl, etc.; hydroxy(lower)alkanoyl such as hydroxyacetyl, etc.; heterocyclic carbonyl such as morpholinecarbonyl [e.g.,  
 15 4-morpholinecarbonyl, etc.], etc.; lower alkylcarbamoyl such as methylcarbamoyl, tert-butylcarbamoyl, etc.; carboxy(lower)alkylamino(lower)alkanoyl such as carboxymethylaminoacetyl, etc.;
- ar(lower)alkylamino(lower)alkanoyl such as mono-, di- or tri-phenyl(lower)alkylamino(lower)alkanoyl [e.g., benzylaminoacetyl, etc.], etc.;
- N-loweralkoxycarbonyl-N-loweralkoxycarbonyl(lower)alkylamino(lower)alkanoyl such as N-tert-  
 20 butoxycarbonyl-N-tert-butoxycarbonylmethyl-aminoacetyl.

R<sup>2</sup> is acyl [e.g., lower alkanoyl (e.g., formyl, acetyl, etc.), arenesulfonyl (e.g., benzenesulfonyl, toluenesulfonyl, etc.), etc.]; carbamoyl(lower)alkyl (e.g., carbamoylmethyl, etc.); esterified carboxy(lower)alkyl [e.g., lower alkoxycarbonyl(lower)alkyl (e.g., ethoxycarbonylmethyl, etc.), etc.]; carboxy(lower)alkyl [e.g., carboxymethyl, etc.] and the like.

- 25 R<sup>3</sup> is ar(lower)alkoxy [e.g., mono-, di- or tri-phenyl(lower)alkoxy (e.g., benzyloxy, phenethyloxy, etc.), etc.]; N-(lower)alkyl-N-ar(lower)alkylamino [e.g., N-methyl-N-benzylamino, N-ethyl-N-benzylamino, etc.] and the like.

- A<sup>1</sup> is glutamine, serine, asparagine, glutamic acid, threonine, lysine, histidine,  $\beta$ -aspartic acid, ornithine, glycine, tyrosine, tryptophan, hydroxypurine, pyroglutamic acid,  $\beta$ -alanine, N<sup>5</sup>, N<sup>5</sup>-di(lower)alkylglutamine,  
 30 N<sup>6</sup>-trihalo(lower)alkoxycarbonyllysine, N<sup>6</sup>-ar(lower)alkoxycarbonyllysine, N<sup>7</sup>-arenesulfonylhistidine, N<sup>5</sup>-ar-(lower)alkoxycarbonylornithine, N<sup>6</sup>-haloar(lower)alkoxycarbonyllisine, O<sup>3</sup>-ar(lower)alkylthreonine, N-loweralkyl-threonine, glutamic acid O<sup>5</sup>-trihalo(lower)alkyl ester, O<sup>3</sup>-carboxy(lower)alkanoylthreonine, and the like.

- A<sup>2</sup> is glycine, phenylglycine, tyrosine, lysine, D-phenylalanine, methylphenylalanine, 3-pyridylalanine, 3-thienylalanine, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, 2,3-dihydroindene-2-amino-2-carboxylic acid,  
 35 and the like.

The method for preparation of the object compound (I) is described as follows.

#### Preparation 1

- 40 The object compound (Ia) or the salt thereof may be prepared by reacting the compound (IIa) or the reactive derivative at the amino group or the salt thereof with the compound (IIb) or the reactive derivative at the carboxy group or the salt thereof.

- Suitable examples of the reactive derivative at amino group of the compound (IIa) include Schiff base type imino or enamine type tautomerism thereof formed by the reaction between the compound (IIa) and  
 45 carbonyl compound such as aldehyde or ketone; silyl derivative formed by the reaction between the compound (IIa) and silyl compound such as bis(trimethylsilyl)acetamide, mono(trimethylsilyl)acetamide, bis-(trimethylsilyl)urea, etc.; the derivative formed by the reaction between the compound (IIa) and phosphorous trichloride or phosgene.; and the like.

- Suitable example of the salt of the compound (IIa) or the reactive derivative thereof should be referred  
 50 to one exemplified for that of the compound (I).

- As suitable reactive derivative at carboxy group of the compound (IIa), acid halide, acid anhydride, activated amide, activated ester are exemplified. Suitable examples of the reactive derivative include acid  
 55 halide; acid azide; mixed acid anhydride such as an anhydride with substituted phosphoric acid (e.g., dialkyl phosphoric acid, phenyl phosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.), dialkyl phosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, sulfonic acid (e.g., methanesulfonic acid, etc.), aliphatic carboxylic acid (e.g., acetic acid, propionic acid, butyric acid, isobutyric acid, pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.), aromatic carboxylic acid (e.g., benzoic acid, etc.) or the like; symmetric acid anhydride; activated amide



with amine such as imidazole, 4-substituted imidazole, dimethylpyrrazole, triazole, tetrazole, or the like; activated ester such as cyanomethyl ester, dimethyliminomethyl[(CH<sub>3</sub>)<sub>2</sub>N=CH-]ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesitylphenyl ester, phenylazophenyl ester, phenylthio ester, p-nitrophenylthio ester, p-crezylthio ester, carboxymethylthio ester, pyranil ester, pyridyl ester, piperikyl ester, 8-quinolylthio ester, or the like; ester with N-hydroxy compound (e.g., N,N-dimethylhydroxylamine, 1-hydroxy-2-(1H)-pyridone, N-hydroxysuccinimide, N-hydroxyphthalimide, 1-hydroxy-1H-benzotriazole, or the like. Thus exemplified reactive derivatives may be selected according to the kind of the compound (Ib).

Suitable examples of salt of the compound (Ib) or the reactive derivative thereof include salt with base such as alkali metal salt (e.g., sodium salt, potassium salt, etc.), alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.), ammonium salt, salt with organic base (e.g., trimethylamine, triethylamine, pyridine, picoline, dicyclohexylamine, N,N'-dibenzylethylenediamine, etc.), or acid addition salt as exemplified as the salt of the compound (I).

The present reaction is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, etc.), acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine, or any other organic solvent which does not adversely affect the proceeding of the reaction. These solvent may be used as a mixture with water.

In the case that the compound (Ib) is used as free acid or the salt thereof, may be used conventional condensing agent such N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide; N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide; N,N'-diethylcarbodiimide; N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide; N,N'-carbonylbis-(2-methylimidazole); pentamethyleneketene-N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1-alkoxy-1-chloroethylene; phosphorous acid trialkyl ester; poly ethyl phosphate, poly isopropyl phosphate; phosphoryl chloride; phosphorous trichloride; diphenylphosphoryl azide; thionyl chloride; oxalyl chloride; lower alkyl haloformate [e.g., ethyl chloroformate, isopropyl chloroformate, etc.]; triphenylphosphine; 2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5-(m-sulfophenyl isoxazolium hydroxide inner salt; 1-(p-chlorobenzenesulfonyloxy)-6-chloro-1H-benzotriazole; Viles-Meyer reagent prepared by reacting N,N-dimethyl-formamide with thionyl chloride, phosgene, trichloromethyl chloroformate, phosphorous oxychloride, etc..

The reaction may be also carried out in the presence of inorganic or organic base such as alkali metal bicarbonate, tri(lower)alkylamine, pyridine, N-(lower)alkylmorpholine, N,N-di(lower)alkylbenzylamine or the like.

The reaction is usually carried out under cooling or warming though the reaction temperature is not limited.

## Preparation 2

The object compound (Ib) or the salt thereof may be prepared by subjecting the compound (Ia) or the salt thereof to eliminating reaction of amino-protective group.

Suitable example of the salt of the compound (Ia) and (Ib) should be referred to the exemplified salts of the compound (I).

The present reaction is carried out according to the conventional hydrolysis or reduction.

The hydrolysis is preferably carried out in the presence of base or acid including Lewis-acid.

Suitable examples of the base include inorganic base and organic base such as alkali metal (e.g., sodium, potassium, etc), alkaline earth metal (e.g., magnesium, calcium, etc.), metal hydroxide, carbonate or bicarbonate thereof, trialkylamine (e.g., trimethylamine, triethylamine, etc.), picoline, 1,5-diazabicyclo[4.3.0]non-5-ene, 1,4-diazabicyclo[2.2.2]octane, 1,8-diazabicyclo[5.4.0]undec-7-ene and the like.

Suitable examples of the acid include organic acid such as formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc., inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, hydrochloride, hydrobromide, hydrofluoride, etc. or acid addition salt such as hydrochloric acid salt of pyridine etc..

The elimination reaction which is used Lewis-acid such as trihaloacetic acid (e.g., trichloroacetic acid, trifluoroacetic acid, etc.) is preferably carried out in the presence of cation catching agent such as anisole, phenol, or the like.

The present reaction is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, etc.), methylene chloride, chloroform, tetrachloromethane, tetrahydrofuran, the mixture thereof or any other organic solvent which does not adversely affect the proceeding of the reaction. Liquid base and acid may also be used as solvent.

The reaction temperature is not limited, and therefore the reaction is usually carried out under cooling

or heating.

Reduction reaction which is applied for the elimination reaction includes chemical reduction and contact reduction.

Suitable examples of the reducing agent which is used for chemical reduction include metal (e.g., tin, zinc, iron, etc.), or the combination of metal compound (e.g., chromic chloride, chromic acetate, etc.) and organic or inorganic acid (e.g., formic acid, acetic acid, propionic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.).

Suitable examples of the catalyst which is used for contact reduction include conventional catalyst such as palladium catalyst (e.g., platinum board, platinum sponge, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.), palladium catalyst (e.g., palladium sponge, palladium-black, palladium oxide, palladium-carbon, colloidal palladium, palladium-barium carbo-nate, palladium-barium sulfonate, etc.), nickel catalyst (e.g., reduced nickel, oxidized nickel, Raney-nickel, etc.), cobalt catalyst (e.g., reduced cobalt, Raney-cobalt, etc.), iron catalyst (e.g., reduced iron, Raney-iron, etc.), copper catalyst (e.g., reduced copper, Raney-copper, Ullman-copper, etc.), and the like.

The reaction is usually carried out in a conventional solvent which does not adversely affect the proceeding of the reaction such as water, methanol, ethanol, propanol, N,N-dimethylformamide, or the mixture thereof.

Liquidous acid which is used for the chemical reduction may also be used as a solvent for the reaction. Suitable examples of solvent for contact reduction include conventional one such as diethyl ether, dioxane, tetrahydrofuran and any other solvent illustrated before and a mixture thereof which does not adversely affect the proceeding of the reaction.

The reaction temperature is not limited, and therefore the reaction is usually carried out under cooling or heating.

#### 25 Preparation 3

The object compound (Ic) or the salt thereof may be prepared by reacting the compound (Ib) or the reactive derivative at the amino group or the salt thereof with the compound (IIc) or the reactive derivative at the carboxy group or the salt thereof.

The suitable salt of the compound (Ib) or the reactive derivative thereof should be referred to that illustrated for the compound (IIa).

The suitable salt of the compound (IIc) or the reactive derivative thereof should be referred to that illustrated for the compound (IIb).

The suitable salt of the compound (Ic) should be referred to that illustrated for the compound (I).

The present reaction is carried out in substantially the same manner to that of Preparation 1, and accordingly, the reaction system and the reaction condition such as the kind of the reactive derivative, kind of solvent, reaction temperature should be referred to that of Preparation 1.

#### 40 Preparation 4

The object compound (Ie) or the salt thereof may be prepared by subjecting the compound (Id) or the salt thereof to eliminating reaction of amino-protective group.

The present reaction is carried out in substantially the same manner to that of Preparation 2, and accordingly, the reaction system and the reaction condition such as the kind of base, acid, reducing agent, catalyst, solvent, temperature, etc. should be referred to that of Preparation 2.

In the present eliminating reaction the amino-protective group of  $R^{1b}$  and/or lower alkyl of  $R^3$  may be eliminated during the course of reaction proceeding or after-treatment, which case is included in the scope of the present invention.

#### 50 Preparation 5

The object compound (If) or the salt thereof may be prepared by subjecting the compound (Ie) or the reactive derivative at amino group or the salt thereof to introducing reaction of amino-protective group.

The present reaction is carried out in substantially the same manner to that of Preparation 1, and accordingly, the reaction system and the reaction condition such as the kind of the reactive derivative, kind of solvent, reaction temperature should be referred to that of Preparation 1.

The compound thus obtained through the above mentioned preparation may be separated and purified by conventional method such as pulverization, recrystallization, column chromatography, reprecipitation, or

the like.

The compound (I) and any other compound of the present invention may include one more than two stereo-isomer due to asymmetric carbon atom, and these isomer or the mixture thereof is included in the scope of the present invention.

The object compound (I) and the salt thereof has a pharmaceutical activity such as tachykinin antagonism, especially substance P compound antagonism, neurokinin A antagonism, neurokinin B antagonism, and the like. Accordingly it is useful for therapeutics or prevention of tachykinin mediated diseases such as respiratory diseases (e.g., asthma, bronchitis, rhinitis, cough, expectoration, etc.), ophthalmic diseases (e.g., conjunctivitis, vernal conjunctivitis, etc.), cutaneous diseases (e.g., contact dermatitis, atopic dermatitis, urticaria, other kind of eczematoid dermatitis, etc.), inflammatory diseases (e.g., rheumatoid arthritis, osteoarthritis, etc.), pains or aches (e.g., migraine, headache, toothache, cancerous pain, backpain, etc.), and the like.

Further the object compound (I) of the present invention are also useful for treating or preventing of other kind of diseases such as ophthalmic diseases (e.g., glaucoma, uveitis, etc.); gastrointestinal diseases (e.g., ulcer, ulcerative colitis, irritable bowel syndrome, food allergy, etc.); inflammatory diseases (e.g., nephritis, etc.); circulatory diseases (e.g., hypertension, angina pectoris, cardiac failure, thrombosis, etc.); epilepsy; spastic paralysis; pollakiuria; dementia; Alzheimer's disease; schizophrenia; Huntington chorea; carcinoid syndrome, and the like.

The object compound (I) or the salt thereof is used in the form of a pharmaceutical preparation, which contains the above compound as an active ingredient in admixture with an organic or inorganic, solid or liquid carrier that is pharmaceutically acceptable and is suitable for peroral, parenteral or external application. The pharmaceutical composition may be prepared as capsule, tablet, sugar coated tablet, granule, solution, suspension, emulsion, or any other form suitable for use, which may include, if necessary, conventional additives such as auxiliary agent, stabilizing agent, wetting agent, emulsifying agent, Doffers, or the like.

The dosage of therapeutically or preventively effective amount of the object compound (I) varies from and also depend upon the age and condition of each individual patient to be treated. An average single dose, for example in effective treatment of asthma, of about 0.1 mg, 1 mg, 50 mg, 100 mg, 250 mg and 1,000 mg is generally administered.

As examples for showing such pharmacological effect of the object compound (I), the pharmacological test data of the representative compound is illustrated as follows.

#### Test method

##### 1. Binding with $^3\text{H}$ -P substance receptor


###### (a) Crude lung membrane preparation

Male Hartly strain guinea pigs were sacrificed by decapitation. The trachea and lung were removed and homogenized in buffer (0.25 M sucrose, 50 mM Tris-HCl pH 7.5, 0.1mM MEDTA) by using Polytron (Kinematica). The homogenate was centrifuged (1000 x g, 10 min) to remove tissue clumps and the supernatant was centrifuges (14000 x g, 20min) to yield pellets. The pellets were resuspended in buffer (5 mM Tris-HCl pH 7.5), homofenized with a teflon homogenizer and centrifuged (14000 x g, 20 min) to yield pellets which were referred to crude membrane fractions. The obtained pallets were stored at -70 °C until use.


###### (b) $^3\text{H}$ -Substance P binding to preparation membrane

Frozen crude membrane fractions were thawed and resuspended in Medium 1 (50 mM Tris-HCl pH 7.5, 5mM  $\text{MnCl}_2$ , 0.02% BSA, 2  $\mu\text{g/ml}$  chymostatin, 4  $\mu\text{g/ml}$  leupeptin, 40  $\mu\text{g/ml}$  bacitracin).  $^3\text{H}$ -substance P (1nM) was incubated with 100  $\mu\text{l}$  of the membrane preparation in Medium 1 at 4° C for 30 minutes in a final volume of 500  $\mu\text{l}$ . At the end of the incubation over a Whatman GF/B glass filter (pretreated with 0.1% polyethylene imine for 3 hours prior to use) under aspiration. The filters were then washed four times with 5 ml of the buffer (50 mM Tris-HCl, pH 7.5). The radioactivity was counted in 5 ml of Aquazol-2 in Packard scintillation counter (Packard TRI-CARB 4530).

#### Test compound



(a) Ac-Thr-D-Trp(CHO)-NH CONMeBzl



(b) Ac-Thr-D-Trp(CHO)-N CONMeBzl

(c) Ac-Thr-D-Trp(CHO)-MePhe-NMeBzl


Result of test	
test compound (1 µg/ml)	suppression rate (%)
(a)	100
(b)	99
(c)	96

In the present specification, the following abbreviations are further used in addition to that appointed in IUPAC-IUB.

Ac	:acetyl
Ac <sub>2</sub> O	:acetic acid anhydride
Boc	:tert-butoxycarbonyl
Bzl	:benzyl
DCHA	:dicyclohexylimine
DIPEA	:diisopropylethylamine
DMF	:N,N-dimethylformamide
DMSO	:dimethylsulfoxide
Et	:ethyl
4N-HCl/DOX	:4N-hydrogenchloride in 1,4-dioxane
HOBT	:N-hydroxybenzotriazole
IPE	:isopropyl ether
Me	:methyl
NMM	:N-methylmorpholine
TFA	:trifluoroacetic acid
THF	:tetrahydrofuran
Tos-Cl	:tosylchloride(p-toluenesulfonylchloride)
TsOH	:p-toluenesulfonic acid (tosylic acid)
WSC	: 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide
WSC·HCl	: 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride


Further, in those examples, in the case wherein amino acid residue has the substituent in wherein

amino acid residue has the substituent in the side chain, for example,



is illustrated as the formula; -Trp(CHO)-.

Still further, in those examples, the following group;



is illustrated as the formula; -NMe(Bzl).

Still further, in those examples, Me-Phe means N-methylphenylalanine.


The present invention is further explained in detail by describing the examples.

#### [Example]


##### Preparative example 1

(1)

Starting compound :



Object compound :




The starting compound (3.30g) was suspended in water (35ml), and were added triethylamine (2.22g) and acetone (10ml). Acetone solution of (Boc)<sub>2</sub>O (4.81g) was added to the above obtained mixture under ice-cooling. The reaction mixture was stirred for 30 minutes at the same temperature, and further for 4 hours after removing off the ice bath. During this stirring, were added dropwise triethylamine (0.44g) and acetone (15ml). Acetone was distilled off from the reaction mixture, and then washed with diethyl ether. The aqueous reaction mixture was changed to acidic solution by adding 1N-HCl. After extracting twice with ethyl acetate, the extracts were gathered and washed twice with brine and dried over anhydrous magnesium sulfate. The extract was condensed under reduced pressure and IPE was added to the residue to give the solidified object compound (3.40g).


NMR(CDCl<sub>3</sub>, δ) : 1.48(9H,s), 3.22(2H,d,J=6 Hz), 4.62(ABq, 4H,J=18Hz), 5.1(1H,m), 7.20(4H,s)-7.96(1H,s)

(2)

Starting compound :



Object compound :




20 The starting compound (3.30g) was dissolved in a mixed solution of ethyl ether (80ml) and ethyl acetate (20ml), and then DCHA(2.05g) was added under ice-cooling. The reaction mixture was condensed to 20ml, and was added IPE(15ml). The resultant solution was kept standing in a cold box for a night. The precipitated crystals were gathered by filtration and dried to give the object compound (2.1g).

mp: 171 - 172 °C


IR (Nujol): 2700- 2600, 2350, 1695, 1630 cm<sup>-1</sup>

(3)

Starting compound;



Object compound;



45 ① The starting compound (2.28g) was added to the mixture of 10% citric acid and ethyl acetate. The organic solution was washed with brine and dried over magnesium sulfate. The solvent was distilled off under reduced pressure to give free acid of the object compound (1.46g).

50 ② Thus obtained compound in ① was dissolved in methylene chloride (25ml), and then were added NMM (502.6mg) and DMF (4ml) to give a clear solution. Thus obtained solution was cooled to -22 ~ -20 °C and was added dropwise methylene chloride (4ml) solution of isobutyl chloroformate (680mg). After stirring for 20 minutes at the same temperature, the reaction mixture was further cooled to -40 °C and was added HNMe(Bzl) (605mg). The reaction mixture was brought back to ambient temperature during stirring for 3.5 hours. After condensation under reduced pressure, extract was carried out by ethyl acetate. The extract was washed respectively with dil. hydrochloric acid, water, dil. aqueous solution of sodium bicarbonate and brine, in turn. After drying over anhydrous magnesium sulfate, the solution was condensed under reduced pressure. The precipitated crystals were washed with n-hexane to give the object compound (463mg).

mp: 99- 100 °C

IR (nujol) 1690, 1660 cm<sup>-1</sup>

NMR(CDCl<sub>3</sub>, δ): 1.45(9H,s), 3.07(5H,broad) 4.4-4.9(4H,m), 5.1(1H,m), 7.31(9H,s)

### Preparative example 2

5 Starting compound;



15 Object compound;



The starting compound (1.5g), benzylalcohol (4.55g) and TsOH·H<sub>2</sub>O (1.76g) were added to 1,2-dichloroethane (35ml), and the reaction mixture was refluxed for 10 hours. During this course, TsOH·H<sub>2</sub>O (300mg) was added. The reaction mixture was condensed, and IPE was added to obtain the crystallized object compound (3.76g).

IR (Nujol): 2650, 2540, 1740, 1225, 1160 cm<sup>-1</sup>

NMR(CDCl<sub>3</sub>, δ): 2.30(3H,s), 3.37(2H,d,J=7Hz), 4.3-4.7 (3H,m), 5.17(2H,s), 7.01 and 7.50- (ABq, 4H, J=8Hz), 7.30(5H,s), 6.95- 7.4 (4H,m), 9.8(2H,broad)

30 [α]<sub>D</sub><sup>25</sup> -39.3° (C = 1.046, MeOH)

### Preparative example 3

(1)

35 Starting compound;



45 Object compound;



The object compound was obtained from the starting compound in a similar manner to that of the preparative example 1-(1).

mp: 131-140 °C


IR (Nujol): 2700-2550, 1710, 1170 cm<sup>-1</sup>

NMR(CDCl<sub>3</sub>, δ): 1.50(9H,s), 3.19(2H,d,J=7Hz), 4.58(2H,dd,J=16Hz), 5.15(1H,m), 7.20(4H,s), 9.62-(1H,s)


$[\alpha]_D^{25} -9.83^\circ$  (C = 1, MeOH)

(2)

Starting compound;



Object compound;



The starting compound (3.5g), HNMe(Bzl) (1.53g) and HOBT (1.71g) was dissolved in DMF (35ml). After WSC·HCl (2.42g) was added under ice-cooling, the reaction mixture was stirred at ambient temperature for 6 hours. During this course, WSC·HCl (0.24g) was added. After concentration, the reaction mixture was extracted with ethyl acetate, and then washed with respectively 2% hydrochloric acid, water, 2% aqueous solution of sodium bicarbonate, water and brine, in order.


After drying by anhydrous magnesium sulfate, it was condensed under reduced pressure. The residue was developed for column chromatography of silica-gel (200g), and then was eluted with firstly chloroform and then with a mixed solution of chloroform and methanol (50:1). The fractions containing the object compound were gathered and condensed under reduced pressure. The residue was developed for column chromatography of silica-gel (60g), and then was eluted with a mixed solvent of ethyl acetate and n-hexane [(1/3) ~ (1/1)]. The fractions containing the object compound were gathered and the solvent was distilled off under reduced pressure to give the oily object compound (4.04g). IR (oil): 1690, 1660, 1165  $\text{cm}^{-1}$

NMR( $\text{CDCl}_3$ ,  $\delta$ ): 1.50(9H, s), 3.05(3H, s), 2.85-3.2(2H, m), 4.4-5.1(4H, m), 5.3(1H, m), 7.2 - 7.5 (9H, m)  
MS: m/e = 380

#### Preparative example 4


(1)

starting compound :



Object compound :







The object compound was obtained from the starting compound in a similar manner to that of the preparative example 1-(1).

NMR(CDCl<sub>3</sub>, δ): 1.25(s) and 1.42(s)(9H), 3.38(2H, d, J=4Hz), 4.58(m) and 5.20(m)(1H), 6.83-7.28-(3H, m), 9.13(1H, s)

(2)  
Starting compound :



Object compound :




To the solution of methylene chloride (25ml) of the starting compound (1.59g), HNMe(Bzl) (679mg) and HOBT(756mg) was added WSC·HCl(1.17g) under ice-cooling. The reaction mixture was stirred for one hour at the same temperature, and further stirred for one night at ambient temperature. After condensation under reduced pressure, the reaction mixture was extracted with ethyl acetate, and then washed respectively with water, dil. aqueous solution of sodium bicarbonate, water, dil. hydrochloric acid and brine in turn. After drying over anhydrous magnesium sulfate, the solution containing the object compound was condensed under reduced pressure. The residue was developed for column chromatography of silica-gel(30g), and then was eluted with chloroform. The fractions containing the object compound were gathered and the solvent was distilled off under reduced pressure to obtain the object compound (2.2g).


NMR(CDCl<sub>3</sub>, δ): 1.4(s) and 1.43(s)(9H), 2.83(s) and 2.92(s)(3H), 3.23(2H, d, J=6Hz), 4.4- 4.6(2H, m), 4.7-5.1(1H, m), 5.4(1H, m), 6.8-7.4 (8H, m)

#### Preparative example 5

Starting compound :



Object compound :




10 The suspended solution of benzyl alcohol (20ml) of the starting compound (3.02g), TsOH (2.17g) dried over P<sub>2</sub>O<sub>5</sub> for 5 hours at 100 °C under reduced pressure and Tos-Cl (2.63g) was refluxed for 3 hours in an oil bath of 90 °C, and then heated for one hour under reduced pressure. After ice-cooling, diethyl ether was added to precipitate the gum-like materials, which were gathered by filtraion and washed with diethyl ether

15 to obtain the powder of the object compound (7.0g).


NMR(D<sub>2</sub>O, δ): 2.35(6H,s), 3.47-3.77(2H,m), 4.90 and 5.20(2H,ABq, J = 12Hz), 7.0-7.5 (m), 7.6-7.8(m) and 8.0-8.3(m)(17H)

Preparative example 6

Starting compound :



Object compound :



45 The object compound was obtained from the starting compound in a similar manner to that of the preparative example 2.

mp: 188-190 °C


IR ( Nujol ) : 2600- 2700, 1750, 1740, 1220, 1175 cm<sup>-1</sup>

NMR(DMSO-d<sub>6</sub>, δ): 2.31(3H,s), 5.27(2H,s), 5.42(1H,s), 7.32(5H,s) ... 7.5(5H,s), 7.13 and 7.53 (4H,ABq, J=8Hz) . 8.93(3H,broad s)


Preparative example 7

(1)

Starting compound :



Object compound :



The object compound was obtained from the starting compound in a similar manner to that of the preparative example 1-(1).


mp: 168 - 168.5 °C (decomp)

IR (Nujol): 3400, 1760, 1660  $\text{cm}^{-1}$


NMR( $\text{CDCl}_3$ ,  $\delta$ ): 1.41(9H,s), 3.21 and 3.68(4H,ABq,  $J=16\text{Hz}$ ), 5.3(1H,broad), 7.21(4H,s), 9.43-(1H,broad)

(2)

Starting compound :



Object compound :



To the solution of DMF (30ml) of the starting compound (3.32g) was added DIPEA (2.29ml) under ice-cooling, and further added benzyl bromide (2.25g). The reaction mixture was stirred for 1.5 hours at the same temperature and further for 3 hours at ambient temperature. The reaction mixture was condensed under reduced pressure and extracted with ethyl acetate. The extract was washed respectively with water, dil. aqueous solution of sodium bicarbonate, water and brine in turn. After drying over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure to obtain the object compound (4.23g).


mp: 107-108 °C

IR (Nujol): 3400, 1735, 1710  $\text{cm}^{-1}$


NMR( $\text{CDCl}_3$ ,  $\delta$ ): 1.38(9H,s), 3.20 and 3.70(4H,ABq,  $J=18\text{Hz}$ ), 5.22(2H,s), 7.20(4H,s), 7.32(5H,s)

(3)

Starting compound :



Object compound :



To the mixture of the starting compound (4.2g) and anisol (4ml) was added TFA(40ml) under ice-cooling. The resultant mixture was stirred for 15 minutes at the same temperature and 25 minutes at ambient temperature. After concentration under reduced pressure, 4N-HCl/DOX(5.7ml) was added thereto and condensed again. IPE was added to the residue to precipitate crystals, which were gathered by filtration to obtain the object compound (3.30g).

mp: 200 °C (decomp)

IR (Nujol) : 2760, 2710, 2610, 2590, 2490, 1735, 1605, 1510, 1232 cm<sup>-1</sup>

#### Preparative example 8

(1)

Starting compound : Boc-MePhe-OH

Object compound : Boc-MePhe-NMe(Bzl)

The object compound was obtained from the starting compound in a similar manner to that of the preparative example 3-(2).

mp: 74-75 °C

IR (Nujol) : 1680, 1645 cm<sup>-1</sup>

NMR(DMSO-d<sub>6</sub>, δ) : 0.94(s), 1.12(s) and 1.27(s)(9H), 2.6-3.1(2H,m), 2.71(3H,s), 2.82(3H,s), 4.2-4.7-(2H,m), 4.9-5.4(1H,m), 6.9-7.4 (10H,m)

(2)

Starting compound : Boc-MePhe-NMe(Bzl)

Object compound : HCl·H-MePhe-NMe(Bzl)

The object compound was obtained from the starting compound in a similar manner to that of the preparative example 7-(3).

IR (Nujol) : 2700, 2450, 1640 cm<sup>-1</sup>

NMR(DMSO-d<sub>6</sub>, δ) : 2.47(3H,s), 2.51(3H,s), 2.7-3.6(2H,m), 4.40(2H,s), 4.64(1H,dd, J=6Hz and 9Hz), 6.9-7.4(10H,m), 9.5(2H,broad s)

#### Preparative example 9

(1)

Starting compound : Boc-MePhe-OH

Object compound : Boc-MePhe-OBzl

The object compound was obtained from the starting compound in a similar manner to that of the preparative example 7-(2).

IR (Film) : 1740, 1705, 1690 cm<sup>-1</sup>

NMR(DMSO-d<sub>6</sub>, δ) : 1.28(9H,s), 2.60(3H,s), 2.9-3.3(2H,m), 4.6-4.9(1H,m), 5.21(2H,s), 7.33(5H,s), 7.44-(5H,s)

(2)

Starting compound : Boc-MePhe-OBzl

Object compound : HCl·H-MePhe-OBzl

The object compound was obtained from the starting compound in a similar manner to that of the


preparative example 7-(3).

IR (Nujol) : 2800-2300, 1740  $\text{cm}^{-1}$


NMR(DMSO- $\text{d}_6$ ,  $\delta$ ) : 2.59(3H,s), 3.12(1H,dd,J=9Hz and 14Hz), 3.44(1H,dd,J=5Hz and 14Hz), 4.36-(1H,dd,J=5Hz and 9Hz), 5.13(2H,s), 7.1-7.4(10H,m), 10.0(2H,broad s)

Preparative example 10

Starting compound :



Object compound :



The object compound was obtained from the starting compound in a similar manner to that of the preparative example 2.


mp: 98- 102 °C (decomp)

IR (Nujol) : 1740, 2750, 2650, 2540, 1225, 1160  $\text{cm}^{-1}$


NMR( $\text{CDCl}_3$ ,  $\delta$ ) : 2.33(3H,s), 3.35(2H,d,J=6Hz), 4.6(2H,broad), 5.18(2H,s), 6.67(1H,broad), 7.03 and 7.57(4H, ABq,J=8Hz), 7.2(4H,s), 7.35(5H,s), 9.73(2H,broad)

Example 1

Starting compound :



Object compound :




① To the starting compound (695mg) was added TFA(11ml) under ice-colling, and then the reaction mixture was stirred for 15 minutes at the same temperature and further for 20 minutes removing off the ice bath. After condensing under reduced pressure, methylene chloride (30ml) was added, and dil. aqueous solution of sodium bicarbonate was further added to neutralize the solution. The organic layer


② To thus obtained dry organic layer were added Boc-D-Trp(CHO)-OH (614mg), HOBT (257mg) and WSC•HCl (363mg). The reaction mixture was stirred for 2 days. During this stir, WSC•HCl(170mg) was added, and then NMM was added to neutralize the reaction mixture, which was then stirred at ambient tempreture. After the reaction was over, the reaction mixture was washed respectively with water, aqueous solution of sodium bicarbonate, dil. hydrochloric acid and brine in turn, and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain the object compound (1.15g).

### Example 2


Starting compound :



[ Intermediate compound :



Object compound :



① To the starting compound (1.15g) was added anisole (1.0ml), and further added TFA (20ml) under ice-cooling. The reaction mixture was stirred for 30 minutes. After condensing under reduced pressure, 4N-HCl/DOX (0.9ml) was added, and further condensed under reduced pressure. IPE was added to obtain the powder of the intermediate compound (1.29g).

② Thus obtained intermediate compound (1.25g), Boc-Thr-OH (401mg) and HOBT (247mg) were dissolved in methylene chloride ( 20ml) , and then WSC(284mg) was added under ice-cooling. The reaction mixture was stirred for 2 hours. During this course, triethylamine was added to control pH 3. After reaction was over, the reaction mixture was condensed and extracted with ethyl acetate. The extract was washed respectively with water, dil. aqueous solution of sodium bicarbonate, 0.5N-HCl and brine in turn. After drying over anhydrous magnesium sulfate, the extract was condensed under reduced

5

## 10



20



30




45


50

IR (Nujol) : 3300, 1710, 1660(sh), 1630  $\text{cm}^{-1}$ NMR( $\text{CDCl}_3$ ,  $\delta$ ) : 1.16(3H,d,J=7Hz), 2.03(3H,s), 2.75- 3.34(7H,m), 3.4- 3.7(1H,m), 4.2- 4.8(6H,m), 5.0- 5.6(2H,m), 6.3-6.6(1H,m), 6.9 - 7.7(13H,m), 8.2(1H,m), 8.82(1H,broad)5 Example 4

Starting compound :



15 Object compound :




30 The starting compound (1.32g), Boc-D-Trp(CHO)-OH (1.0g) and HOBT (406mg) were added to the mixed solvent of methylene chloride (20ml) and DMF(5ml), and WSC(513mg) was added thereto under ice-collig. The reaction was stirred for 2 hours under at the same temperture. The reaction mixture was kept standing for 3 days at 5°C, and condensed under reduced pressure. The residue was extracted with ethyl acetate, and then was washed respectively with dil. aqueous solution of sodium bicarbonate, dil. hydrochloric acid and brine in turn. After drying over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure to obtain the object compound (1.76g).


35 NMR( $\text{CDCl}_3$ ,  $\delta$ ) : 1.45(s) and 1.50(s)(9H), 2.8-3.4(4H,m), 4.1-4.9(2H,m), 5.2-5.7(2H,m), 6.5(1H,m), 7.0-7.7(9H,m), 8.2(1H,m), 8.9(1H,m)

40 Example 5

Starting compound :



50 Object compound :





The object compound was obtained from the starting compound in a similar manner to that of example 2 by using Boc-Gln-OH in stead of e Boc-Thr-OH.

mp: ~ 82 °C

IR ( Nujol ) : 3300, 1710, 1660, 1170 cm<sup>-1</sup>


NMR(CDCl<sub>3</sub>, δ) : 1.35(s) and 1.43(s)(9H), 1.9-2.4 (4H,m), 3.0 - 3.3(4H,m), 4.3(3H,m), 4.86(s) and 5.02(s)-(2H), 5.2 - 5.5(2H,m), 5.8(1H,m), 6.3(1H,m), 6.9 - 7.4 (14H,m), 7.6(2H,m), 8.1(1H,m), 8.92(1H,s)

Chemical analysis as C<sub>39</sub>H<sub>43</sub>N<sub>5</sub>O<sub>8</sub> · 2H<sub>2</sub>O


Calculation	C 62.86,	H 6.35,	N 9.38
Found	C 62.49,	H 5.73,	N 9.11

#### Example 6

Starting compound :



Object compound :



To the solution of methylene chloride (5ml) of the starting compound (1.38g) and anisole (2ml) was added TFA(12ml) under ice-cooling. The reaction mixture was stirred for 15 minutes at the same temperature and further 1.15 hour at ambient temperature. After condensation under reduced pressure, 4N-HCl/DOX (1.8ml) was added thereto, and the resultant mixture was condensed again. The residue was dissolved in methylene chloride and washed with dil. aqueous solution of sodium bicarbonate, and then dried over anhydrous magnesium sulfate. Then, DMF, BOC-D-Trp(CHO)-OH (603mg) and HOBT(246mg) were added thereto. To the resultant mixture was added WSC·HCl(350mg) under ice-cooling. The mixture was kept standing for several hours to return ambient temperature and stirred for one night at the same temperature. During this course, Boc-D-Trp(CHO)-OH (603mg) and WSC·HCl (350ml) was added thereto. After condensation under reduced pressure, the residue was extracted with ethyl acetate. The extract was washed respectively with water, dil. aqueous solution of sodium bicarbonate, dil. hydrochloric acid and brine in turn. After drying over anhydrous magnesium sulfate, the residue was developed for column chromatography of silica-gel (40g) and eluted with chloroform. The fractions containing the object compound was gathered and dried under reduced pressure to obtain the object compound (1.74g).

NMR(CDCl<sub>3</sub>, δ) : 1.40(s) and 1.48(s)(9H), 2.8-3.2(7H,m), 4.4-4.8(4H,m), 5.0-5.6(2H,m), 6.4(1H,broad), 6.9-7.8(14H,m), 8.3(1H,broad), 9.84(1H,broad)

#### Example 7

(1)



$$\text{Boc-D-Trp(CHO)-N} \begin{array}{c} \diagup \\ \text{(L)} \end{array} \text{CONMe(Bz1)}$$

15

$$\text{Boc-Thr-D-Trp(CHO)-N} \begin{array}{c} \diagup \\ \text{(L)} \end{array} \text{CONMe(Bzl)}$$

The object compound was obtained from the starting compound in a similar manner to that of the preparative example 7 by using Boc-Thr-OH in stead of Boc-Gln-OH.

NMR(DMSO-d<sub>6</sub>, δ ): 1.03(3H,d,J = 7Hz), 1.38(9H,s), 2.65-3.2(7H,m), 3.7-4.1(3H,m), 4.3-4.8(4H,m), 5.15-5.4(2H,m), 6.33(1H,d,J = 7Hz), 6.8-7.7(14H,m), 8.2(1H,m), 9.1(1H,broad)

### Example 9

30

$$\text{Boc-Thr-D-Trp (CHO)} - \text{N} \begin{array}{c} \diagup \text{---} \text{C}_6\text{H}_5 \\ \diagdown \text{---} \text{CH}_2 \\ \text{(L) CONMe (Bzl)} \end{array}$$


[ Intermediate compound :

40

$$\text{HCl} \cdot \text{H-Thr-D-Trp (CHO)} - \text{N} \begin{array}{c} \diagup \text{---} \text{Benzene ring} \\ \diagdown \text{---} \text{CH}_2 \text{---} \text{CH}_2 \text{---} \text{CH}_2 \text{---} \text{CONMe (Bzl)} \end{array}$$

45

55



10 ① TFA (20ml) was added to the mixture of the starting compound (0.88g) and anisole (1.0ml) under ice-cooling. The reaction mixture was stirred for 17 minutes at the same temperature and then for 1.15 hour at ambient temperature. After condensation under reduced pressure, 4N-HCl/DOX (0.65ml) was added thereto and condensed again. IPE was added to obtain the powder of the intermediate compound (682mg).

15 ② To thus obtained intermediate compound (682mg), DIPEA (279mg) was added under ice-cooling, and further added methylene chloride (0.85ml) solution of AcCl(85mg). After condensing under pressure, the reaction mixture was extracted with ethyl acetate and washed respectively with water, dil. aqueous solution of sodium bicarbonate, dil. hydrochloric acid and brine in turn. The ethyl acetate solution was dried over anhydrous magnesium sulfate and the solvent was distilled off under reduced pressure. The residue was developed for column chromatography of silica-gel (25g) and eluted with firstly chloroform, and then with a mixture of chloroform-methanol (100:2.5). The fractions containing the object compound was condensed under reduced pressure and IPE was added to obtain the powder of the object compound (522mg).

IR (Nujol): 3300, 1710, 1640(sh), 1630  $\text{cm}^{-1}$


25 NMR(DMSO- $d_6$ ,  $\delta$ ): 0.90(d) and 1.00(d)(3H, J = 7Hz), 1.87(3H,s), 2.6-3.2(7H,m), 3.7-4.1(2H,m), 4.1-5.9(6H,m), 5.2(1H,m), 6.8-7.5(14H,m), 7.7(1H,m), 8.1(1H,d, J = 8Hz), 9.05- (1H,broad)

#### Example 10

30 Starting compound:



40 Object compound:




50 The object compound was obtained from the starting compound in a similar manner to that of example

4.


NMR( $\text{CDCl}_3$ ,  $\delta$ ): 1.19(s) and 1.36(s)(9H), 3.1(4H,m), 4.15-4.75(2H,m), 4.94(s) and 4.96(s)(2H), 5.1-5.6 (2H,m), 6.4-6.8(1H,m), 6.9-7.5(13H,m), 8.7(1H,m), 8.3(1H,broad), 8.85(1H,broad)

#### Example 11

Starting compound:



Object compound:



20 The object compound was obtained from the starting compound by using Boc-Gln-OH in stead of Boc-Thr-OH in a similar manner to that of example 2. mp: 90- 107 °C

IR ( Nujol ) : 3300, 1740(sh), 1710, 1660 cm<sup>-1</sup>

NMR(CDCl<sub>3</sub>, δ) : 1.34(s) and 1.40(s)(9H), 1.78- 2.4(4H,m), 3.0-3.4(4H,m), 4.0-4.6(2H,m), 4.7-5.58(3H,m), 5.7-6.35(3H,m), 6.9-7.45(13H,m), 7.5-7.8(3H,m), 8.2(1H,m), 9.0(1H,broad)


25

Chemical analysis as C <sub>39</sub> H <sub>43</sub> N <sub>5</sub> O <sub>8</sub>			
Calculated	C 65.99,	H 6.11 ,	N 9.87
Found	C 64.94,	H 6.27 ,	N 9.39


30

### Example 12

Starting compound:



Object compound:



The object compound was obtained from the starting compound in a similar manner to that of example

1.


# EP 0 515 681 A1

mp: 86- 88° C  
 IR ( Nujol ) : 3300, 1710, 1665, 1620, 1530 cm<sup>-1</sup>  
 NMR(DMSO-d<sub>6</sub>, δ ) : 1.29(9H,s), 2.74(s) and 2.92(s)(3H), 2.8-3.2(4H,m), 4.1-4.7 (3H,m), 4.8-5.2(1H,m), 6.7-7.4(11H,m), 7.45-8.8(2H,m), 8.1(1H,broad), 8.5-8.8(1H,m), 9.35(1H,broad)


Chemical analysis as C <sub>32</sub> H <sub>36</sub> N <sub>4</sub> O <sub>5</sub> S				
calculated	C 65.29,	H 6.16,	N 9.52,	S 5.45
Found	C 65.11,	H 6.09,	N 9.10,	S 5.44

## Example 13

Starting compound:



Object compound:




The object compound was obtained from the starting compound by using Boc-Thr-OH in stead of Boc-Gln-OH in a similar manner to that of example 7.


NMR(DMSO-d<sub>6</sub>, δ ) : 0.89(3H,d,J=6Hz), 1.34(9H,s), 2.77 and 2.89(3H,s), 2.7-3.4(4H,m), 3.6-4.0(2H,m), 4.2-5.1 (5H,m), 6.26(1H,m), 6.7-7.8(13H,m), 8.1(1H,m), 8.65 (1H,m), 9.3(1H,m)

## Example 14

Starting compound:



Object compound:



10 The object compound was obtained from the starting compound in a similar manner to that of example 9.

mp: 191 - 192 °C  
 IR ( Nujol ) : 3300, 1710, 1660(sh), 1645(sh), 1630, 1530 cm<sup>-1</sup>  
 NMR(DMSO-d<sub>6</sub>, δ ) : 0.79(3H,d,J = 6Hz), 1.86(3H,s), 2.77(s) and 2.89(s)(3H), 2.75-3.3(4H,m), 3.6-3.9-(1H,m), 3.96-4.3(1H,m), 4.38-5.1(5H,m), 6.7-7.8(13H,m), 7.95-8.25(2H,m), 8.55-8.8-(1H,m), 9.2(1H,broad)

Chemical analysis as C <sub>33</sub> H <sub>37</sub> N <sub>5</sub> O <sub>6</sub> S • ½ H <sub>2</sub> O			
Calculated	C 61.84,	H 6.13,	N 10.92
Found	C 62.12,	H 5.96,	N 10.76

#### Example 15

Starting compound: TsOH•H-Tyr-OBzl

Object compound: Boc-D-Trp(CHO)-Tyr-OBzl

The object compound was obtained from the starting compound in a similar manner to that of example

4.

mp: ~ 167 °C  
 IR ( Nujol ) : 3480, 3320, 1720, 1690, 1655, 1545, 1530 cm<sup>-1</sup>  
 NMR(DMSO-d<sub>6</sub>, δ ) : 1.29(9H,s), 2.6-3.2(4H,m), 4.2-4.7 (2H,m), 5.12(2H,s), 6.64(2H,d,J = 8Hz), 6.7-7.0 (1H,m), 7.03(2H,d,J = 8Hz), 7.3-7.9(9H,m), 8.0-8.3 (1H,m), 8.4-8.6(1H,m), 9.22(1H,s)-9.4(1H,broad)

Chemical analysis as C <sub>33</sub> H <sub>35</sub> N <sub>3</sub> O <sub>7</sub> • 2H <sub>2</sub> O			
Calculated	C 63.76,	H 6.32,	N 6.76
Found	C 63.97,	H 6.04,	N 6.80

#### Example 16

Starting compound: Boc-D-Trp(CHO)-Tyr-OBzl

Object compound: HCl•H-D-Trp(CHO)-Tyr-OBzl

The object compound was obtained from the starting compound in a similar manner to that of example

2 ①.

NMR(DMSO-d<sub>6</sub>, δ ) : 2.6-3.2(4H,m), 4.0-4.3(1H,m), 4.4-4.7 (1H,m), 5.13(2H,s), 6.67(2H,d,J = 8Hz), 7.03-(2H,d, J = 8Hz), 7.2-7.5(7H,m), 7.6-7.8(2H,m), 8.1-8.5 (4H,broad), 9.2-9.5(2H,m), 9.40-(1H,s)

#### Example 17

Starting compound: HCl•H-D-Trp(CHO)-Tyr-OBzl

Object compound: Boc-Gln-D-Trp(CHO)-Tyr-OBzl

The object compound was obtained from the starting compound by using Boc-Gln-OH in stead of Boc-Thr-OH in a similar manner to that of example 2 ①.

mp: ~ 203 °C (decomp)  
 IR ( Nujol ) : 3310, 1695, 1680, 1645, 1515 cm<sup>-1</sup>  
 NMR(DMSO-d<sub>6</sub>, δ ) : 1.32(9H,s), 1.5-2.1(4H,m), 2.7-3.1 (4H,m), 3.7-4.1(1H,m), 4.3-4.9(2H,m), 5.09(2H,s), 6.63(2H,d, J = 8Hz), 6.7-6.9(1H,m), 7.01(2H,d, J = 8Hz), 7.1-7.7(11H,m), 7.8-8.3(2H,m), 8.5-8.7(1H,m), 9.20(1H,s), 9.3(1H,broad)

Chemical analysis as C <sub>38</sub> H <sub>43</sub> N <sub>6</sub> O <sub>9</sub> * 3/4 H <sub>2</sub> O			
Calculated	C 62.76,	H 6.17,	N 9.63
Found	C 62.76,	H 6.03,	N 9.72

#### Example 18

Starting compound: TsOH·H-D-Phe-OBzl

Object compound: Boc-D-Trp(CHO)-D-Phe-OBzl

The object compound was obtained from the starting compound in a similar manner to that of example 4.

mp: ~ 146 °C (decomp)  
 IR ( Nujol ) : 3350, 1725, 1680, 1660, 1525 cm<sup>-1</sup>  
 NMR(DMSO-d<sub>6</sub>, δ ) : 1.26(9H,s), 2.7-3.2(4H,m), 4.1-4.8 (2H,m), 5.10(2H,s), 6.8-7.1(1H,m), 7.2-7.5(2H,m), 7.25(5H,s), 7.35(5H,s), 7.5-7.8(2H,m), 8.2(1H, broad), 8.50(1H,broad d, J = 9Hz), 9.4 (1H,broad)

Chemical analysis as C <sub>33</sub> H <sub>35</sub> N <sub>3</sub> O <sub>6</sub>			
Calculated	C 69.58,	H 6.19,	N 7.38
Found	C 69.99,	H 6.53,	N 7.45

#### Example 19

Starting compound : Boc-D-Trp(CHO)-D-Phe-OBzl

Object compound : HCl·H-D-Trp(CHO)-D-Phe-OBzl

The object compound was obtained from the starting compound in a similar manner to that of example 2 ①.

IR ( Nujol ) : 1710, 1675, 1550 cm<sup>-1</sup>  
 NMR(DMSO-d<sub>6</sub>, δ ) : 2.9-3.5(2H,m), 3.09(2H,d, J = 7Hz), 4.0-4.4 (1H,m), 4.66(1H,q, J = 7Hz), 5.09(2H,s), 7.1-7.5 (2H,m), 7.28(5H,s), 7.32(5H,s), 7.72 (1H,s), 7.8-8.1 (1H,m), 8.1-8.4(1H,m), 8.42-(3H,broad s), 9.4(1H, broad), 9.41(1H,broad d, J = 7Hz)

#### Example 20

Starting compound : HCl·H-D-Trp(CHO)-D-Phe-OBzl

Object compound : Boc-Gln-D-Trp(CHO)-D-Phe-OBzl

The object compound was obtained from the starting compound by using Boc-Gln-OH in stead of Boc-Thr-OH in a similar-manner to that of example 2 ②.


mp: 208 - 209 °C  
 IR ( Nujol ) : 3310, 1720, 1690, 1650(broad), 1525 cm<sup>-1</sup>  
 NMR(DMSO-d<sub>6</sub>, δ ) : 1.34(9H,s), 1.4-2.1(4H,m), 2.8-3.2 (4H,m), 3.7-4.1(1H,m), 4.4-4.8(2H,m), 5.07(2H,s), 6.6-7.0(2H,m), 7.1-7.5(3H,m), 7.27(5H,s), 7.34 (5H,s), 7.5-7.8(2H,m), 7.9-8.3(2H,m), 8.4-8.7 (1H,m), 9.3(1H,broad)




Chemical analysis as: C <sub>38</sub> H <sub>43</sub> N <sub>5</sub> O <sub>8</sub>			
Calculated	C 65.41,	H 6.21,	N 10.04
Found	C 66.00,	H 6.24,	N 10.25

## Example 21

Starting compound :



Object compound :




The object compound was obtained from the starting compound in a similar manner to that of example

4. NMR(DMSO-d<sub>6</sub>, δ): 1.28(9H,s), 2.80(2H,m), 3.20(2H,m), 4.30(1H,m), 4.88(1H,q, J = 6Hz), 6.90-  
 (1H,d, J = 6Hz), 7.37(5H,s), 7.2-7.85(12H,m), 8.18(1H,broad), 8.4-8.7(2H,m), 9.40-  
 (1H,broad)


Chemical analysis as: C <sub>32</sub> H <sub>34</sub> N <sub>4</sub> O <sub>6</sub>			
Calculated	C 67.35,	H 6.00,	N 9.82
Found	C 66.31,	H 5.60,	N 9.59

## Example 22

Starting compound :



Object compound :



10 The object compound was obtained from the starting compound in a similar manner to that of example 2 ①.


mp: 217 °C (decomp)

IR (Nujol): 3130, 2700-2500, 1740, 1715(sh), 1700(sh), 1690 cm<sup>-1</sup>


15 NMR(DMSO-d<sub>6</sub>, δ): 3.15(2H,m), 3.65(2H,m), 4.13(1H,m), 4.95(1H,m), 5.21(2H,s), 7.45(5H,s), 7.72(1H,s), 7.8-8.9(8H,m), 9.48(1H,broad s), 9.90(1H,d, J = 8Hz), 10.9 (3H,broad s)

### Example 23

20 Starting compound:



Object compound:



45 The object compound was obtained from the starting compound by using Boc-Gln-OH in stead of Boc-Thr-OH in a similar manner to that of example 2 ②.

mp: 161 - 162 °C

IR (Nujol): 3330, 1720, 1690, 1640 cm<sup>-1</sup>


50 NMR(DMSO-d<sub>6</sub>, δ): 1.31(9H,s), 1.6(2H,m), 1.85(2H,m), 2.83 (2H,m), 3.15(2H,m), 3.95(1H,m), 4.7(2H,m), 5.11 (2H,s), 6.75(2H,m), 7.1-7.7(8H,m), 7.35(5H,s), 8.1 (2H,m), 8.48(1H,m), 8.7(1H,m), 9.28(1H,m)

Chemical analysis as: C<sub>37</sub> H<sub>42</sub> N<sub>6</sub> O<sub>8</sub>


Calculated	C 63.60,	H 6.06,	N 12.03
Found	C 62.83,	H 5.78,	N 11.78

### Example 24

Starting compound :



Object compound :



The object compound was obtained from the starting compound in a similar manner to that of example

25 2 ① .

IR ( Nujol ) :


3450-3200, 2750-2600, 1740, 1710(sh), 1695, 1670  $\text{cm}^{-1}$

NMR(DMSO- $d_6$ ,  $\delta$ ) :


1.7-2.1(4H,m), 2.8-3.2(2H,m), 3.6-4.1 (3H,m), 4.4-4.7(1H,m), 4.9-5.2(1H,m), 5.18(2H,s),  
6.8-7.0(2H,m), 7.32(5H,s), 7.3-8.7(12H,m), 8.83 (1H,d, J=6Hz), 9.11(2H,m), 9.40-  
(1H,broad)

30 Example 25

Starting compound :



Object compound :



The object compound was obtained from the starting compound in a similar manner to that of example

4.

mp:

144 - 145 °C

IR ( Nujol ) :

3450, 1740, 1715, 1690, 1650  $\text{cm}^{-1}$ NMR(DMSO- $\text{d}_6$ ,  $\delta$ ) :


1.41(9H,s), 3.18(2H,d, J = 6Hz), 4.45-4.8 (1H,m), 5.12(2H,s), 5.58(1H,d, J = 6Hz), 5.25 (1H,d, J = 6Hz), 6.9-7.8(15H,m), 8.1-8.5(1H,m), 8.85(1H,broad)

Chemical analysis as  $\text{C}_{32} \text{H}_{33} \text{N}_5 \text{O}_6$ 


Calculated	C 69.17,	H 5.99,	N 7.56
Found	C 69.15,	H 6.04,	N 7.53

Example 26

Starting compound :



Object compound :



The object compound was obtained from the starting compound in a similar manner to that of example

7.

mp:

194 - 195 °C (decomp)

IR ( Nujol ) :

3430(Sh), 3310, 3200(Sh), 1710, 1690, 1660(Sh), 1640, 1530, 1170  $\text{cm}^{-1}$ NMR(DMSO- $\text{d}_6$ ,  $\delta$ ) :

1.32(9H,s), 1.47-2.17(4H,m), 2.9-3.1 (2H,m), 3.7-4.2(1H,m), 4.73-5.1(1H,m), 5.18- (2H,s), 5.56(1H,d, J = 7Hz), 6.7-7.0(2H,m), 7.1-7.8(15H,m), 8.0-8.3(1H,m), 9.1- (1H,d, J = 7Hz), 9.3(1H,broad)

Chemical analysis as  $\text{C}_{37} \text{H}_{41} \text{N}_5 \text{O}_8$ 



calculated	C 65.00,	H 6.04,	N 10.24
Found	C 63.92,	H 5.89,	N 10.28

Example 27

Starting compound :



Object compound :



The object compound was obtained from the starting compound in a similar manner to that of example

4.

mp: 164- 165 °C



IR ( Nujol ) : 3400, 3320, 1730, 1700, 1655  $\text{cm}^{-1}$

NMR( $\text{CDCl}_3$ ,  $\delta$ ) : 1.35(9H,s), 2.95-3.91(6H,m), 4.0-4.6 (1H,m), 5.18(2H,s), 6.65(1H,m), 7.2-7.7(5H,m), 7.15 (4H,s), 7.32(5H,s), 8.3(1H,broad), 8.9(1H,broad)



Chemical analysis as $\text{C}_{34} \text{H}_{35} \text{N}_3 \text{O}_6$			
calculated	C 70.21,	H 6.06,	N 7.22
Found	C 70.23,	H 6.17,	N 7.17

### Example 28

Starting compound :



Object compound :



The object compound was obtained from the starting compound in a similar manner to that of example

2.

mp: 162 - 164 °C

IR ( Nujol ) : 3300, 1740(sh), 1710, 1680(sh), 1660  $\text{cm}^{-1}$

NMR( $\text{DMSO-d}_6$ ,  $\delta$ ) : 1.31(9H,s), 1.5-2.1(4H,m), 2.8-4.1 (6H,m), 4.5-4.9(2H,m), 5.12(2H,s), 6.6-7.0(2H,m), 7.1-7.8(5H,m), 7.22(4H,s), 7.36(5H,s), 8.0-8.4 (2H,m), 8.8(1H,broad), 9.3(1H,broad)

EP 0 515 681 A1

Chemical analysis as C <sub>39</sub> H <sub>43</sub> N <sub>5</sub> O <sub>8</sub>			
calculated	C 65.99,	H 6.1,	N 9.87
Found	C 65.00,	H 6.2,	N 9.44

Example 29

Starting compound : HCl·H-MePhe-NMe(Bzl)

Object compound : Boc-D-Trp(CHO)-MePhe-NMe(Bzl)

The object compound was obtained from the starting compound by using Boc-D-Trp(CHO)-OH in stead of Boc-Thr-OH in a similar manner to that of example 2 ②.

mp: 76- 78 ° C

IR ( Nujol ) : 3530, 3220, 1710, 1640cm<sup>-1</sup>

NMR(DMSO-d<sub>6</sub>, δ) : 1.24(9H,s), 2.5-3.2(4H,m), 2.81(3H,s), 2.93(3H,s), 4.2-4.8(3H,m), 5.5-5.8(1H,m), 6.8-7.7 (15H,m), 8.1(1H,broad), 9.3(1H,broad)

Example 30

Starting compound : Boc-D-Trp(CHO)-MePhe-NMe(Bzl)

Object compound : Boc-Thr-D-Trp(CHO)-MePhe-NMe(Bzl)

The object compound was obtained from the starting compound in a similar manner to that of example 2.

mp: 70- 85 ° C

IR ( Nujol ) : 3400(broad), 1710, 1640cm<sup>-1</sup>

NMR(DMSO-d<sub>6</sub>, δ) : 0.87(3H,broad d, J=6Hz), 1.29(s) and 1.34(s)(9H), 2.5-3.2(4H,m), 2.70(s) and 2.74(s) (3H), 2.92(3H,s), 3.5-4.1(2H,m), 4.2-5.0(4H,m), 5.4-5.7(1H,m), 5.9-6.3 (1H,m), 6.8-7.6 (14H,m), 7.8-8.3(2H,m), 9.2(1H,broad)

Example 31

Starting compound : Boc-Thr-D-Trp(CHO)-MePhe-NMeBzl

Object compound : Ac-Thr-D-Trp(CHO)-MePhe-NMeBzl

The object compound was obtained from the starting compound in a similar manner to that of example 3.

mp: 85- 90 ° C

IR ( Nujol ) : 3320(broad), 1710, 1640 (broad)cm<sup>-1</sup>

NMR(DMSO-d<sub>6</sub>, δ) : 0.85(3H,d, J=6Hz), 1.80(s) and 1.87(s) (3H), 2.5-3.2(4H,m), 2.75(3H,s), 2.95(3H,s), 3.6-4.0 (1H,m), 4.0-4.35(2H,m), 4.35-5.1(3H,m), 5.5-5.8 (1H,m), 6.8-7.8(15H,m), 7.9-8.3 (2H,m), 9.3(broad s)

Chemical analysis as C <sub>36</sub> H <sub>41</sub> N <sub>5</sub> O <sub>6</sub> · ¾ H <sub>2</sub> O			
calculated	C 66.19,	H 6.56,	N 10.72
Found	C 66.05,	H 6.28,	N 10.49

Example 32

Starting compound : HCl·H-MePhe-OBzl

Object compound : Boc-D-Trp(CHO)-MePhe-OBzl

The object compound was obtained from the starting compound in a similar manner to that of example 4.

mp: 105 - 107 ° C

IR ( Nujol ) : 3400, 1725, 1715, 1690, 1640, 1520 cm<sup>-1</sup>

NMR(DMSO-d<sub>6</sub>, δ) : 1.30(9H,s), 2.5-3.4(4H,m), 2.85(3H,s), 4.4-4.8(1H,m), 4.9-5.4(1H,m), 5.17(2H,s), 7.0-7.7 (5H,m), 7.25(5H,s), 7.38(5H,s), 7.9-8.4(1H,m), 9.4(1H,broad),

Chemical analysis as C <sub>34</sub> H <sub>37</sub> N <sub>3</sub> O <sub>6</sub>			
calculated	C 69.97,	H 6.39,	N 7.20
Found	C 70.11,	H 6.46,	N 7.18

**Example 33**

Starting compound : Boc-D-Trp(CHO)-MePhe-OBzl

Object compound : HCl•H-D-Trp(CHO)-MePhe-OBzl

The object compound was obtained from the starting compound in a similar manner to that of example 2 ①.

IR ( Nujol ) : 3400(broad), 1740, 1710, 1660 cm<sup>-1</sup>

NMR(DMSO-d<sub>6</sub>, δ) : 2.5-3.5(4H,m), 2.90(3H,s), 4.5-4.8 (1H,m), 5.0-5.4(1H,m), 5.19(2H,s), 7.0-7.8(4H,m), 7.27(5H,s), 7.38(5H,s), 8.1-8.4(1H,m), 8.5(3H, broad s), 9.4(1H,broad)

**Example 34**

Starting compound : HCl•H-D-Trp(CHO)-MePhe-OBzl

Object compound : Boc-Gln-D-Trp(CHO)-MePhe-OBzl

The object compound was obtained from the starting compound by using Boc-Gln-OH in stead of Boc-Thr-OH in a similar manner to that of example 2 ②.

mp: 87- 90 °C

IR ( Nujol ) : 3250, 1740, 1710, 1660, 1640, cm<sup>-1</sup>

NMR(DMSO-d<sub>6</sub>, δ) : 1.34(9H,s), 1.5-2.1(4H,m), 2.5-3.4 (4H,m), 2.81(3H,s), 3.8-4.2(1H,m), 4.8-5.4(2H,m), 5.16(2H,s), 6.75(2H,broad s), 7.0-7.7(5H,m), 7.24 (5H,s), 7.38(5H,s), 8.0-8.4(2H,m), 9.3-(1H,broad)

**Industrial Utilizability**

Newly provided peptide compound provided in the present invention has a pharmaceutical activity such as anti-tachykinin effect, especially anti-substance P compound effect, anti-neurokinin A effect, anti-neurokinin B effect, and the like. Accordingly, the present invention provides useful means for therapeutics or prevention of tachykinin intersitial diseases of human or animals such as respiratpry diseases (e.g., asthma, bronchitis, rhinitis cough, expectoration, etc.), optical diseases (e.g., conjunctivitis, vernal conjunctivitis, etc.), dertic diseases (e.g., contact dermatitis, atopic dermatitis, urticaria, other kind of eczematoid deratitis, etc.) inflammatory diseases (e.g., chronic rheumatism, esteoarthritis, etc.), pain of every kind ( e.g., migraine, cephalalgia toothach, cancerous pain, backach, etc.), and the like.

**Claims**

1. A compound of the general formula:



[wherein

R<sup>1</sup> is hydrogen or amino-protective groupR<sup>2</sup> is amino-protective groupR<sup>3</sup> is ar(lower)alkoxy or N-(lower)alkyl or N-ar(lower)alkylaminoA<sup>1</sup> is single bond or one amino acid residueA<sup>2</sup> is one amino acid residue excepting Phe.] or the salt thereof

2. A process for the preparation of the compound of the general formula:



[wherein R<sup>1a</sup>, R<sup>2</sup>, R<sup>3</sup>, A<sup>2</sup> are each as defined above] or the salt thereof  
by reacting the compound of the general formula:

H - A<sup>2</sup> - R<sup>3</sup>

[wherein A<sup>2</sup> and R<sup>3</sup> are each as defined above]  
with the compound of the general formula:

R<sup>1a</sup> - D - Trp(R<sup>2</sup>)- O H

[wherein R<sup>1a</sup> is amino-protective group, R<sup>2</sup> is as defined above] or the reactive derivative at the carboxy group, or the salt thereof.

3. A process for the preparation of the compound of the general formula:

H - D - Trp(R<sup>2</sup>)- A<sup>2</sup> - R<sup>3</sup>

[wherein R<sup>2</sup>, R<sup>3</sup>, A<sup>2</sup> are each as defined above] or the salt thereof  
by subjecting the compound of the general formula:

R<sup>1a</sup> - D - Trp(R<sup>2</sup>)- A<sup>2</sup> - R<sup>3</sup>

[wherein R<sup>1a</sup>, R<sup>2</sup>, R<sup>3</sup>, A<sup>2</sup> are each as defined above] or the salt thereof  
to elimination reaction of the amino-protective group.

4. A process for the preparation of the compound of the general formula:

R<sup>1b</sup> - D - Trp(R<sup>2</sup>)- A<sup>2</sup> - R<sup>3</sup>

[wherein R<sup>1b</sup>, R<sup>2</sup>, R<sup>3</sup>, A<sup>2</sup> are each as defined above] or the salt thereof  
by reacting the compound of the general formula:

H - D - Trp(R<sup>2</sup>)- A<sup>2</sup> - R<sup>3</sup>

[wherein R<sup>2</sup>, R<sup>3</sup> and A<sup>2</sup> are each as defined above] or the reactive derivative at the amino group, or the salt thereof

with the compound of the general formula:

R<sup>1b</sup> - A<sup>1</sup> - O H

[wherein R<sup>1b</sup> is amino-protective group, A<sup>1</sup> is as defined above] or the reactive derivative at the carboxy group, or the salt thereof.

5. A process for the preparation of the compound of the general formula:

H - A<sup>1</sup> - Trp(R<sup>2</sup>)- A<sup>2</sup> - R<sup>3</sup>

[wherein R<sup>2</sup>, R<sup>3</sup>, A<sup>1</sup> and A<sup>2</sup> are each as defined above] or the salt thereof  
by subjecting the compound of the general formula:

R<sup>1b</sup> - A<sup>1</sup> - D - Trp(R<sup>2</sup>)- A<sup>2</sup> - R<sup>3</sup>

[wherein R<sup>1b</sup>, R<sup>2</sup>, R<sup>3</sup>, A<sup>1</sup> and A<sup>2</sup> are each as defined above] or the salt thereof  
to elimination reaction of the amino-protective group.


6. A process for the preparation of the compound of the general formula:

R<sup>1c</sup> - A<sup>1</sup> - Trp(R<sup>2</sup>)- A<sup>2</sup> - R<sup>3</sup>

[wherein R<sup>1c</sup>, R<sup>2</sup>, R<sup>3</sup>, A<sup>1</sup> and A<sup>2</sup> are each as defined above] or the salt thereof



by subjecting the compound of the general formula:



[wherein  $R^2$ ,  $R^3$ ,  $A^1$  and  $A^2$  are each as defined above] or the reactive derivative at the amino group, or the salt thereof to amino introducing reaction.

7. A tachykinin-antagonistic agent including the compound of the general formula:



[wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $A^1$  and  $A^2$  are each as defined above] or the salt thereof as an active ingredient in admixture with carrier that is pharmaceutically acceptable.

# Amended claims

Received at International Bureau of WIPO on 21.06.91

Claim 1 of the original one is amended. Other claims are not amended.

## 1. Amended

A compound of the general formula:




[wherein

$R^1$  is hydrogen or amino-protective group  
 $R^2$  is amino-protective group  
 $R^3$  is ar(lower)alkoxy or N-(lower)alkyl-N-ar(lower)alkylamino  
 $A^1$  is single bond or one amino acid residue  
 $A^2$  is one amino acid residue excepting Phe.] or the salt thereof

2. A process for the preparation of the compound of the general formula:



[wherein  $R^{1a}$ ,  $R^2$ ,  $R^3$ ,  $A^2$  are each as defined above] or the salt thereof by reacting the compound of the general formula:




[wherein  $A^2$  and  $R^3$  are each as defined above] with the compound of the general formula:




[wherein  $R^{1a}$  is amino-protective group,  $R^2$  is as defined above] or the reactive derivative at the carboxy group, or the salt thereof.

3. A process for the preparation of the compound of the general formula:




[wherein  $R^2$ ,  $R^3$ ,  $A^2$  are each as defined above] or the salt thereof by subjecting the compound of the general formula:




[wherein  $R^{1a}$ ,  $R^2$ ,  $R^3$ ,  $A^2$  are each as defined above] or the salt thereof to elimination reaction of the amino-protective group.


4. A process for the preparation of the compound of the general formula:



[wherein  $R^{1b}$ ,  $R^2$ ,  $R^3$ ,  $A^2$  are each as defined above] or the salt thereof  
by reacting the compound of the general formula:




[wherein  $R^2$ ,  $R^3$  and  $A^2$  are each as defined above] or the reactive derivative at the amino group, or the salt thereof  
with the compound of the general formula:




[wherein  $R^{1b}$  is amino-protective group,  $A^1$  is as defined above] or the reactive derivative at the carboxy group, or the salt thereof.

5. A process for the preparation of the compound of the general formula:




[wherein  $R^2$ ,  $R^3$ ,  $A^1$  and  $A^2$  are each as defined above] or the salt thereof  
by subjecting the compound of the general formula:



[wherein  $R^{1b}$ ,  $R^2$ ,  $R^3$ ,  $A^1$  and  $A^2$  are each as defined above] or the salt thereof  
to elimination reaction of the amino-protective group.

6. A process for the preparation of the compound of the general formula:




[wherein  $R^{1c}$ ,  $R^2$ ,  $R^3$ ,  $A^1$  and  $A^2$  are each as defined above] or the salt thereof  
by subjecting the compound of the general formula:



[wherein  $R^2$ ,  $R^3$ ,  $A^1$  and  $A^2$  are each as defined above] or the reactive derivative at the amino group, or the salt thereof to amino introducing reaction.

7. A tachykinin-antagonistic agent including the compound of the general formula:



[wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $A^1$  and  $A^2$  are each as defined above] or the salt thereof  
as an active ingredient in admixture with carrier that is pharmaceutically acceptable.

# INTERNATIONAL SEARCH REPORT

International Application No PCT/JP91/00167

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int. Cl <sup>5</sup> C07K5/06, 5/08, A61K37/02		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System <sup>1</sup>	Classification Symbols	
IPC	C07K5/00, A61K37/00	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b>		
Category <sup>6</sup>	Citation of Document, <sup>11</sup> with Indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	JP, A, 1-287095 (Fujisawa Pharmaceutical Co., Ltd.), November 17, 1989 (17. 11. 89), Lower right column, page 8 to upper right column, page 9 & EP, A, 333174	1-7
<p>* Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
April 10, 1991 (10. 04. 91)	April 30, 1991 (30. 04. 91)	
International Searching Authority	Signature of Authorized Officer	
Japanese Patent Office		

Form PCT/ISA/210 (second sheet) (January 1985)

**THIS PAGE BLANK (USPTO)**